Dr. Ware presented his annual lecture entitled “New Techniques for Health Outcomes Measurement and Evaluation” at the Measurement, Design, and Analysis Methods for Health Outcomes Research course held from August 17-19 at the Harvard School of Public Health. The lecture covered noteworthy milestones in the history of patient-reported outcomes (PRO) as well as some of the most innovative and important recent conceptual and methodological advances. The latter included a new generation of standardized (both content and scoring) disease-specific PROs that fill the gap between widely-used disease-specific measures that are not QOL and generic QOL measures that are not disease-specific. In the afternoon workshop, entitled “Integrating Generic and Disease-Specific Assessments: What Are the Issues?” Dr. Ware discussed how both the content and scoring of disease-specific QOL impact measures can be standardized across diseases and how norm-based scoring of disease-specific measures can be accomplished in the chronically-ill population. The recently-published QOL Disease-Specific Impact Scale (QDIS®) was used to illustrate how the convergent and discriminant validity of disease-specific QOL impact ratings is being tested among adults with multiple comorbid conditions (MCC) in an ongoing NIH/AHRQ-sponsored study. A second case study from an ongoing national registry will focus on a powerful new adaptive survey logic that automatically adapts to the presence of MCC while also estimating outcomes equivalent to the metrics underlying widely-used legacy PROs without administering the latter. Despite the more comprehensive information collected in this small-sample field test, surveys were faster for most patients in comparison with state-of-the-art PRO surveys that were administered in parallel.